https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-06 09:26:182023-06-14 16:08:25Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-05 17:44:162023-06-14 16:08:17IXICO to Present Abstracts at Upcoming Huntington’s Disease and Ataxia Conferences
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-29 10:52:312023-06-14 16:13:28Neuraxpharm enters booming CBD market with the acquisition of leading Switzerland-based S.T.U GMBH
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-28 09:18:332023-06-14 16:13:25IXICO announces client contracts and appointment of Chief Business Officer
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-22 09:55:512023-06-14 16:13:20Kiadis Pharma announces formation of renowned Scientific Advisory Board
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-17 12:28:542023-06-14 16:14:41Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-15 10:17:552023-06-14 16:13:17IXICO Company reports fast tracked achievement of initial year positive EBITDA, 40% revenue growth and strong cash position
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-15 10:14:562023-06-14 16:13:10Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-13 09:59:122023-06-14 16:12:10ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-07 13:13:352023-06-14 16:13:03Castor Announces International Expansion to Meet Growing Demand for an AI-Powered Clinical Data Platform
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-07 12:27:072023-06-14 16:12:54Owkin publishes breakthrough research in Nature Medicine
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-01 09:54:162023-06-14 16:12:51Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-09-24 09:34:252023-06-14 16:12:46Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-09-24 09:32:562023-06-14 16:12:18Neuraxpharm provides business update on a transformational year
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-07-13 11:38:282023-10-12 11:12:49Optimum’s 11th Annual Healthcare Investor Conference
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-02-06 17:30:582023-06-14 16:12:24HOX THERAPEUTICS TO PRESENT AT 2019 AACR ANNUAL MEETING
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2018-12-18 12:33:472023-06-14 16:12:36DelSiTech and Innovare Sign Licensing Agreement for the Development of a Long Acting HIV Therapy
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2018-12-17 09:00:272023-10-12 11:14:05Optimum Strategic Communications Expands Investor Relations & Corporate Communications in Switzerland
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2018-11-27 11:21:462023-06-14 16:09:46Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2018-11-27 09:08:472023-06-14 16:09:41INKEF Capital Appoints Roel Bulthuis as Managing Director to Co-Manage Eur 500m FundFor more information about Optimum Strategic Communications, please get in touch.
